Bekim Sadikovic, LHSC Research Chair in Clinical Genomics and Epigenomics, shared a post on LinkedIn:
“Just published in The Journal of Molecular Diagnostics: the first prospective Canadian study demonstrating the real-world clinical impact of broad, pan-cancer genomic profiling in advanced solid tumors.
This work represents the cornerstone study of the POWER precision oncology program — a multi-year effort designed to rigorously evaluate how expanded genomic testing influences care across broader cancer indications. In over 550 patients, comprehensive profiling frequently uncovered clinically actionable findings, often beyond what prior tumor-specific testing had revealed, directly informing treatment decisions, trial access, and therapeutic sequencing.
Importantly, this program — and this study — exists because of the Verspeeten Clinical Genome Centre, made possible through the exclusive and visionary support of the Verspeeten family (Verspeeten Cartage Ltd.). Their commitment is deeply personal and their goal has always been clear: to ensure that precision oncology is not exceptional, but accessible — especially for patients across Southwestern Ontario.
These data provide the evidence needed to move comprehensive genomic profiling from ‘select cases’ toward a more foundational role in routine cancer care — translating precision medicine from promise into practice. With sincere gratitude to the Verspeeten family for making this work possible.”
Svetlana Nikic, Founder of Precision Oncology Consulting, shared Bekim Sadikovic’s post, adding:
“Real-world evidence reinforcing the value of Comprehensive Genomic Profiling (CGP).
New data from the Canadian POWER study (554 advanced solid tumours) demonstrate the tangible clinical and system-level impact of pan-cancer CGP compared with tumour-specific panels:
- 79% of patients harboured clinically relevant variants
- 28% had a change in treatment eligibility following identification of novel druggable alterations
- 18% gained access to clinical trials or off-label therapies with expected improved outcomes
- Among patients previously tested with tumour-specific panels, 19% experienced a change in management after CGP assessment.
I would apreciate if someone can share the PDF of the full publication. Thank you!”
Title: Health Care Impact of Comprehensive Genomic Profiling of Solid Tumors in Patient Management Using POWER (Precision Oncology at Western University)
Authors: Pratibha Bhai, Jacob Turowec, Lee-Anne Pickard, Sadegheh Haghshenas, Karimi Karim, Haley McConkey, Stephanie Santos, Jennifer Kerkhof, Morgan Black, Daniel Breadner, Matthew Cecchini, Christopher Howlett, Laila Schenkel, Emilie Lalonde, Veera Panuganty, Jacques Raphael, Ana Elisa Lohmann, Eric Winquist, John Lenehan, Paul Stewart, Elena Tsvetkova, Mark Vincent, Ricardo Fernandes, Glenn Bauman, Stephen Welch, Bekim Sadikovic
Read the Full Article.
More posts featuring Svetlana Nikic.